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In vitro and in vivo analysis of a novel highly selective β1-adrenoceptor partial agonist. 
Jillian Baker, Shailesh Mistry, Peter Fischer, Stephen Hill, Sheila Gardiner, Barrie Kellam. university of 
Nottingham, Queen's Medical Centre, NG7 2UH, UK 
β-adrenoceptor antagonists (β-blockers) are widely used and save lives in people with heart disease 
due to blockade of β1-adrenoceptors in the heart.  Unfortunately, current β-blockers have poor β1 vs 
β2-adrenoceptor selectivity and are therefore contraindicated in people with asthma due to their 
bronchoconstrictor effects via the β2-adrenoceptors in the lungs.  This means that people with both 
asthma and heart disease are unable to take these life prolonging drugs.  We have previously 
investigated current β-blockers and found them to have poor selectivity in both cellular assays and in 
whole animals (Baker et al., 2011). 
 
We therefore initiated a programme to develop highly selective β1-antagonists.  Here we report a 
novel and highly selective partial agonist for the  1-adrenoceptor: SM64 1-{2-[(3-{4-[2-
(cyclopropylmethoxy)ethoxy]phenoxy}-2-hydroxypropyl)amino]ethyl}-3-(4-hydroxyphenyl)urea. 
 
The pharmacological properties of SM64 were investigated using 3H-cAMP accumulation in cells 
stablyl expressing the human β1 and β2-adrenoceptors and in conscious, atropine-treated freely 
moving, adult male Sprague-Dawley rats, instrumented for measurement of heart rate (β1) and 
hindquarters conductance (β2) as previously described (Baker et al., 2011). 
 
At the human β1-adrenoceptor, SM64 stimulated an increase in 3H-cAMP accumulation (log EC50 = -
8.05 ± 0.04, 51.7 ± 1.7% maximum isoprenaline, n=5).  It behaved as a typical partial agonist, 
inhibiting cimaterol agonist responses to give a log KD of -7.76 ± 0.06 n=15 (by the partial agonist 
method of Stephenson, 1956).  Even at maximal concentrations (10µM, stimulation 9.3 ± 0.09% 
isoprenaline maximum, n=5) it caused minimal shift of the cimaterol concentration response curve at 
the human β2-adrenoceptor giving a log KD of -5.01 ± 0.07 (n=5).  SM64 is therefore 457 times β1 
over β2 selective. 
 
In conscious rats, SM64 (2mg/kg bolus, 1mg/kg/h infusion) caused an increase in basal heart rate  
(from 424 ± 9 bpm to 465 ± 3bpm = 44% of the response to 120ng/kg/min isoprenaline, n=4 animals) 
in keeping with its partial agonist actions observed in the cell studies. Furthermore SM64 significantly 
inhibited the β1-mediated heart rate responses to isoprenaline (at 12, 40 and 120ng/kg/min) whilst 
having no effect on the β2-mediated hindquarters response (n=4 rats), consistent with its β1-
selectivity. 
 
In conclusion, SM64 is a high affinity β1-adrenoceptor partial agonist as demonstrated in cell studies 
and in conscious rats.  A molecule of this selectivity or greater, devoid of partial agonist effects, could 
prove a very useful therapy for people with heart disease and asthma. 
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